Poland· PL-100227976
Cidimus
A l04aa05 product containing tacrolimusum, registered in Poland by Sandoz GmbH. The same ATC class is registered in 2 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
L04aa05 is registered in 2 of 19 countries.
Countries holding a registration under ATC L04AA05 (l04aa05), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 1 of them publish a price we can compare per daily dose
L04aa05 · ATC L04AA05
2 / 19 countries
- Ireland
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- Tacrolimusum
- Manufacturer
- Sandoz GmbH
- Country
- Poland (PL)
- ATC code
- L04AA05
- ATC class
- L04AA05
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 4
- gtin05909990783533
- gtin05909990783540
- gtin05909990783557
- gtin05909990783564
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
L04aa05 in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatestacrolimusGlenmark Pharmaceuticals Inc., USA
- NetherlandsAdport 5 mg, capsules, hardSandoz B.V.
- FinlandAdportSandoz A/S
- United KingdomAdoport 5mg capsulesSandoz Ltd
- SwedenAdoport 5 mg Kapsel, hårdUAB BIJON medica
- CzechiaPROGRAFAstellas Pharma s.r.o., Praha
- SwitzerlandAdvagraf
- SpainADOPORT 5 mg CAPSULAS DURAS EFGSandoz Farmaceutica S.A.
Authorised across Europe · EMA
The same active substance is authorised in 30 EEA countries. Names it is sold under:
- Austria · Adport, Dailiport
- Belgium · Adoport, Dailiport
- Bulgaria · Програф
- Cyprus · Prograf, Tacrolimus Accord
- Czechia · Dailiport, Gecrol
- Germany · Crilomus, Dailiport
- Denmark · Adport, Dailiport
- Estonia · Dailiport, Lebsanan
- Spain · Adoport, Cellmune
- Finland · Adport, Adport,
- France · Adoport, Conferoport
- United Kingdom (Northern Ireland) · Adoport, Ascezo
- Greece · Atodrit-Dermo, Eczatope Derm
- Croatia · Atezyrix, Dermitopic
- Hungary · Prograf, Tacrolimus Stada
- Ireland · Prograf, Tacrolimus Accord
- Iceland · Advagraf, Dailiport
- Italy · Adoport, Carelimus
- Liechtenstein · Advagraf, Envarsus
- Lithuania · Dailiport, Lebsanan
- Luxembourg · Prograft, Sumilor
- Latvia · Dailiport, Lebsanan
- Malta · Prograf
- Netherlands · Adport, Conferoport
- Norway · Adport, Advagraf
- Portugal · Adoport, Dermitopic
- Romania · Prograf, Tacrolimus Sandoz
- Sweden · Adport, Adport,
- Slovenia · Adoport, Dailiport
- Slovakia · Atezyrix, Dailiport
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f0134735-755d-4f71-853e-ed4675e630bd GET /v1/drugs/f0134735-755d-4f71-853e-ed4675e630bd?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Kapsułki twarde",
"source": "urpl",
"strength": "5 mg",
"packaging": "05909990783533 ¦ Rp ¦ 58555\n30 kaps.\n05909990783540 ¦ Rp ¦ 58556\n50 kaps.\n05909990783557 ¦ Rp ¦ 58557\n60 kaps.\n05909990783564 ¦ Rp ¦ 58565\n100 kaps.",
"substance": "Tacrolimusum 5.11 mg",
"common_name": "Tacrolimusum",
"pl_product_id": "100227976",
"pozwolenie_nr": "16851",
"auth_procedure": "DCP",
"authorisation_validity": "Bezterminowe"
}See everything about l04aa05.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.